CAJ | 학술논문

利妥昔单抗是第一个被批准用于淋巴瘤治疗的单克隆抗体。在弥漫大B细胞性淋巴瘤、滤泡淋巴瘤等B细胞非霍奇金淋巴瘤中取得了显著疗效。对于诱导治疗获得缓解后的滤泡淋巴瘤，利妥昔单抗维持治疗可进一步改善患者预后，为治疗指南所推荐。随着淋巴瘤治疗方案的不断改进，如何更好地把握维持治疗的适应症并进一步优化现有的治疗策略，成为研究的热点。本文通过总结分析近年来的相关文献，对利妥昔单抗用于淋巴瘤维持治疗的最新进展进行综述。
리타석단항시제일개피비준용우림파류치료적단극륭항체。재미만대B세포성림파류、려포림파류등B세포비곽기금림파류중취득료현저료효。대우유도치료획득완해후적려포림파류，리타석단항유지치료가진일보개선환자예후，위치료지남소추천。수착림파류치료방안적불단개진，여하경호지파악유지치료적괄응증병진일보우화현유적치료책략，성위연구적열점。본문통과총결분석근년래적상관문헌，대리타석단항용우림파류유지치료적최신진전진행종술。
Rituximab is the first monoclonal antibody that has been approved for the treatment of lymphoma. Rituximab has shown significant efficacy in the treatment of B-cell non-Hodgkin's lymphomas, such as diffuse large B-cell and follicular lymphomas. Maintenance therapy with rituximab has further improved the prognosis in patients with follicular lymphoma. These patients responded to induction treatment. This antibody treatment has been recommended in treatment guidelines. The treatment strategy for lymphoma has continuously improved. Recent studies focused on how to improve the definition of the indication for maintenance therapy and how to optimize the current maintenance regimens. In this review, we summarized the main studies and the most recent advances on ritux-imab maintenance therapy in patients with lymphoma.